Articles

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy;Hematology Division, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark
Clinical Epidemiology, Città della Salute e della Scienza and CPO Piemonte, Torino, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland;Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland;Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland
Danish Cancer Society Research Center, Copenhagen, Denmark
Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, "Sapienza" University of Rome, Roma, Italy
Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Department of Oncology, Oslo University Hospital, Oslo, Norway
Department of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy
First Unit of Pathology, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Unit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy
Department of Oncology, Università di Torino, Torino, Italy;Department of Diagnostics and Public Health, University of Verona, Verona, Italy
Department of Oncology, Lund University Hospital, Lund, Sweden
Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
Hematology, Ospedale degli Infermi, Rimini, Italy
Lymphoma Unit, Department of Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milano, Italy
Department of Hematology, Rigshospitalet, Copenhagen, Denmark;Biotech Research and Innovation Centre, Copenhagen, Denmark
Department of Hematology, Ospedale Generale, Bolzano, Italy
Oncology Unit, Humanitas/Gavazzeni Clinic, Bergamo, Italy
Universita’ della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
SC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
Vol. 105 No. 6 (2020): June, 2020 https://doi.org/10.3324/haematol.2018.214056